PROBIOMED’S PRODUCTION CENTERS ENDORSED WITH GMP CERTIFICATION BY COFEPRIS
The Mexican health authority –now one of the most recognized in the world– recently awarded the badge to the 3 production centers of the biopharmaceutical company.
Mexico City, June 7, 2019. – Today, the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) granted PROBIOMED’s Biotechnology Center in Tenancingo, State of Mexico the Certificate of Good Manufacturing Practices, which supports that it meets the requirements for its operation in accordance with applicable regulations, ensuring the production of quality, safe and effective health supplies.
The facilities of the Mexican biopharmaceutical in San Esteban and Yácatas, Mexico City, received the same badge on May 31st and March 21st of this year, respectively.
Since January 2018 COFEPRIS is member of the Pharmaceutical Inspection Cooperation Scheme (PIC/S) -which brings together the most important regulatory agencies in the world- thanks to the efforts of the Mexican authority to align its processes to international standards in the matter.
“Having our 3 production centers certified by the health authority is a reflection of an excellent teamwork on the part of our plant employees and all areas of the company, I encourage them to continue along this path of adherence to compliance, efficiency and passion for quality “said Juan Carlos Jaimes, Operations Director of the company.
“This achievement means a great effort from our people and a great investment of our company to comply with one of the strictest regulations in the world, I am proud of our team as this allows us to strengthen our competitiveness and reiterate the commitment we have with the medical community and the patients who consume our products” concluded Jaime Uribe Wiechers, CEO of PROBIOMED.
About PROBIOMED
PROBIOMED is a Mexican biopharmaceutical company focused on research, development, manufacture and commercialization of pharmaceutical products for human health. We employ more than 800 men and women and operate 3 manufacturing facilities that comply with the strictest national and international regulation.
Since our establishment, in 1970, we have worked to provide millions of people around the globe with high-technology and affordable solutions that help improve health and quality of life. Our portfolio is composed of a wide range of chemical synthesis generics and high-tech biosimilars for the prevention and treatment of autoimmune and chronic-degenerative diseases, hematological and metabolic disorders, as well as malignant neoplasms, among other conditions.
